Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that the company was awarded the 2021 Startup Village Award from the prestigious MICCAI Society at the 24th Annual International Conference on Medical Image Computing & Computer Assisted Intervention. Deepcell was recognized as the overall winner for its innovation in applying AI to images of cells for biological research applications.
Deepcell was spun out of Stanford University in 2017 to re-invent single-cell analysis by creating a new quantitative dimension of cell morphology. Since then, the company has developed its AI-powered technology to characterize, identify, and sort cells based on visual features.
“Deepcell is pioneering an approach to apply advanced computational image processing to live cells in a way that has never been done before,” said Mahyar Salek, Deepcell’s co-founder and Chief Technology Officer. “Winning the MICCAI award is a powerful endorsement of what Deepcell is doing to advance cell biology with our proprietary microfluidic and imaging system and our deep learning models for cell characterization. Our novel platform is designed to help unlock deeper biological insights that are relevant for basic and translational research and future clinical applications.”
At the MICCAI conference, which attracts leading biomedical scientists, engineers and clinicians, judges evaluated Deepcell in a head-to-head contest of 10 finalist startups competing in front of an audience from around the world for one of the highest-profile recognitions in the field of medical imaging and AI. Deepcell received the highest average score across all categories, including technological advancement, potential impact, accessibility, and relevance to the MICCAI mission.
The company continues to increase its traction. Deepcell is expanding its partnerships with leading academic centers and the biopharma industry, as well as continuing to present data at scientific conferences. The company also continues to build the industry’s largest repository of cell images and associated computationally defined cellular visual features.
For more information about Deepcell, go to www.deepcell.com.
Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Menlo Park, CA. For more information, please visit deepcellbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005380/en/